RA-9

• CAT Number: I015180
• CAS Number: 919091-63-7
• Molecular Formula: C₁₉H₁₅N₃O₅
• Molecular Weight: 365.34
• Purity: ≥95%
• Target: Apoptosis
• IUPAC Name: (3E,5E)-3,5-bis[(4-nitrophenyl)methylidene]piperidin-4-one
• InChI: InChI=1S/C19H15N3O5/c23-19-15(9-13-1-5-17(6-2-13)21(24)25)11-20-12-16(19)10-14-3-7-18(8-4-14)22(26)27/h1-10,20H,11-12H2/b15-9+,16-10+
• InChIKey: YUYPWAMLWZVHAE-KAVGSWPWSA-N
• SMILES: C\1NC/C(=C\C2=CC=C(C=C2)[N+](=O)[O-])/C(=O)/C1=C/C3=CC=C(C=C3)[N+](=O)[O-]

RA-9 (Cat No.:I015180) is a potent and selective inhibitor of proteasome-associated deubiquitinating enzymes (DUBs) with a favorable toxicity profile and demonstrated anticancer activity. It effectively blocks ubiquitin-dependent protein degradation without affecting 20S proteasome proteolytic activity. RA-9 selectively induces apoptosis in ovarian cancer cell lines and primary cultures, and it triggers endoplasmic reticulum (ER)-stress responses in ovarian cancer cells. In vitro studies show that RA-9 inhibits the growth of ovarian cancer cell lines and induces cell cycle arrest and caspase-mediated apoptosis. In vivo, RA-9 suppresses human ovarian cancer cell growth and extends survival in a mouse model. RA-9 holds potential as a therapeutic agent for ovarian cancer treatment.

Reference

[1]. Coughlin K, et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res. 2014;20(12):3174-3186.